ArticleClinical & experimental ophthalmology2025
Low-Cost New Glaucoma Drainage Device in Indonesia: One Year Follow-Up of 252 Subjects.
Article in Clinical & experimental ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative In Vitro Evaluation of Tube Resistance in Glaucoma Drainage Devices with Intraluminal Polypropylene Threads.Bioengineering (Basel, Switzerland) · 2026Article
- Low-Cost New Glaucoma Drainage Device in Indonesia: One Year Follow-Up of 252 Subjects.Clinical & experimental ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the early efficacy and safety of a new polymethyl methacrylate 200 mm
methodsThis was a prospective study following subjects with various forms of refractory glaucoma aged ≥ 7 years old followed for 12 months. The subjects had IOP measurements and biomicroscopy examination preoperatively and at 1, 3, 6 and 12 months timepoints. We noted anti-glaucoma medication use and additional interventions during follow-up. Success was defined as an IOP > 5 and ≤ 21 mmHg on no medications (complete) or medications (qualified).
resultsThere were 252 subjects, 31% (79/252) primary glaucoma and 69% (173/252) secondary glaucoma. All primary glaucoma had previous surgery. The majority of secondary glaucoma was post-vitrectomy and silicone oil insertion 35.6% (62/174). The mean pre-op IOP was 36.8 ± 12.2 mmHg and the 12 months post op IOP was 14.2 ± 6.6 mmHg. The qualified success rate was 89% at 1 year and the complete success was 57%. Mean medication use dropped from 3.5 to 1.3. Certain subtypes (Silicone oil and POAG) appeared to experience greater IOP reduction, however they also had greater preoperative IOP.
conclusionThis new GDD has comparable IOP lowering outcomes compared with other non-valved glaucoma drainage devices during 1 year follow up with similar complication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.